Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s

Navigating neuroimaging in Alzheimer disease care

PET imaging is playing an increasingly critical role in managing AD, but how can you effectively integrate it into clinical practice? Our expert-led program will empower you with practical strategies and real-world case studies.

This content is intended for healthcare professionals outside of the UK.
ADVANCED SEARCH
Log in
Top
Diabetes Therapy
Published in:

Open Access 09-05-2024 | Type 2 Diabetes | Review

Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects

Authors: Luis A. Vázquez, Santiago Tofé-Povedano, Diego Bellido-Guerrero, Marta Botella-Serrano, Alfonso Soto-González, Pedro Mezquita-Raya, Elías Delgado, Carmen Fajardo-Montañana, Cristóbal Morales-Portillo, Ana Causanilles, Miriam Rubio-de Santos, Irene Romera, Esteban Jódar-Gimeno

Published in: Diabetes Therapy | Issue 7/2024

Login to get access

Abstract

Tirzepatide is a novel antidiabetic medication a single-molecule, agonist to the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. It is approved in the USA and EU for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Due to the potential novelty represented by incorporating tirzepatide to clinical practice, we aim to review practical aspects of tirzepatide use in T2DM and the supporting scientific evidence. A group of ten endocrinologists involved as investigators in the phase 3 SURPASS clinical trial program followed a nominal group technique, a qualitative research methodology designed as a semi-structured group discussion to reach a consensus on the selection of a set of practical aspects. The scientific evidence for tirzepatide has been reviewed with respect to a number of patients’ clinical profiles and care goals. Information of interest related to adverse events, special warnings and precautions, and other considerations for tirzepatide use has been included. Finally, information provided to the patients has been summarized. The practical aspects reported herein may be helpful in guiding physicians in the use of tirzepatide and contribute to optimizing the management of T2DM.
Literature
1.
2.
Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules [Internet]. 2022;27(13):4315.
3.
Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388–96.CrossRefPubMed
4.
Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–55.CrossRefPubMed
5.
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.CrossRefPubMed
6.
Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583–98.CrossRefPubMed
7.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811–24.CrossRefPubMed
8.
Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534–45.CrossRefPubMedPubMedCentral
9.
De Block C, Bailey C, Wysham C, Hemmingway A, Allen SE, Peleshok J. Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective. Diabetes Obes Metab. 2023;25(1):3–17.CrossRefPubMed
10.
Potter M, Gordon S, Hamer P. The nominal group technique: a useful consensus methodology in physiotherapy research. N Z J Physiother. 2004;32:126.
11.
Gallagher M, Hares T, Spencer J, Bradshaw C, Webb I. The nominal group technique: a research tool for general practice? Fam Pract. 1993;10(1):76–81.CrossRefPubMed
12.
Moore CM. Applied social research methods series. Group techniques for idea building. Thousand Oaks: Sage Publications; 1987.
13.
Tang KC, Davis A. Critical factors in the determination of focus group size. Fam Pract. 1995;12(4):474–5.CrossRefPubMed
14.
Leitner DR, Frühbeck G, Yumuk V, Schindler K, Micic D, Woodward E, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies—EASO can lead the way. Obes Facts. 2017;10(5):483–92.CrossRefPubMedPubMedCentral
15.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.CrossRefPubMedPubMedCentral
16.
Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394–405.CrossRefPubMed
17.
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):88.CrossRefPubMedPubMedCentral
18.
Boye K, Thieu V, Lee C, Sapin H. Higher weight loss is associated with improved patient reported outcomes in T2D patients treated with tirzepatide. Diabetes Res Clin Pract. 2023;197:110305.
19.
Matza LS, Stewart KD, Landó LF, Patel H, Boye KS. Exit interviews examining the patient experience in clinical trials of tirzepatide for treatment of type 2 diabetes. Patient. 2022;15(3):367–77.CrossRefPubMedPubMedCentral
20.
Eli Lilly and Company. Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (SURMOUNT-OSA). ClinicalTrials.gov identifier: NCT05412004. Updated October 23, 2023. Accessed October 26, 2023. https://​clinicaltrials.​gov/​study/​NCT05412004.
21.
Eli Lilly and Company. A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT). ClinicalTrials.gov identifier: NCT04847557. Updated October 23, 2023. Accessed October 26, 2023. https://​clinicaltrials.​gov/​study/​NCT04847557.
22.
23.
Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418–29.CrossRefPubMed
24.
Rosenstock J, Frias J, Robdbard H, Tofe S, Sears E, Huh R, et al. 750-P: “SURPASS(ing)” an era of basal-bolus insulin therapy—tirzepatide vs. insulin lispro TID added-on to poorly controlled basal insulin-treated in type 2 diabetes. Diabetes. 2023;72 (Supplement_1):750.
25.
Rosenstock J, Vázquez L, Del Prato S, Franco DR, Weerakkody G, Dai B, Landó LF, Bergman BK, Rodríguez A. Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials. Diabetes Care. 2023;46(11):1986–92. https://​doi.​org/​10.​2337/​dc23-0872
26.
Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2018;42(3):416–26.CrossRefPubMedPubMedCentral
27.
Aleppo G, De Block C, Levine JA, Gomez Valderas E, Benneyworth BD. Glycemic control with tirzepatide in people with type 2 diabetes by baseline HbA1c ≤8.5% or >8.5% (717-P). American Diabetes Association 82nd Scientific Sessions; New Orleans, Louisiana; June 3–7, 2022.
28.
Kwan A, Ward JM, Gomez Valderas E, Benneyworth BD, Brown K. Efficacy and safety of tirzepatide in people with type 2 diabetes with poor-control baseline HbA1c according to NCQA-HEDIS performance measures: a post hoc analysis of SURPASS-2, SURPASS-3, and SURPASS-4 Academy of Managed Care Pharmacy; March 29–April 1; Chicago, IL. 2022.
29.
Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393–406.CrossRefPubMed
30.
Eli Lilly and Company. A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT). ClinicalTrials.gov identifier: NCT04255433. Updated October 19, 2023. Accessed January 4, 2024. https://​clinicaltrials.​gov/​ct2/​show/​NCT04255433.
31.
Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. Endocr Pract. 2023;29(5):305–40.CrossRefPubMed
32.
Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA(1c) values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care. 2021;44(10):2231–7.CrossRefPubMedPubMedCentral
33.
Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson A-M, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–44.CrossRefPubMed
34.
Reyes-García R, Moreno-Pérez Ó, Tejera-Pérez C, Fernández-García D, Bellido-Castañeda V, López de la Torre Casares M, et al. A comprehensive approach to type 2 diabetes mellitus—a recommendation document. Endocrinología, Diabetes y Nutrición (English Ed). 2019;66(7):443–58.
35.
Małecki MT, Batterham RL, Sattar N, Levine JA, Rodríguez Á, Bergman BK, Wang H, Ghimpeteanu G, Lee CJ. Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4. Diabetes Care. 2023;46(12):2292–99. https://​doi.​org/​10.​2337/​dc23-1135
36.
Hill A. Patient–practitioner communication in diabetes and diabetes-related foot complications. The Diabetic Foot Journal. 2020;23(2):56–61.
37.
Linetzky B, Jiang D, Funnell MM, Curtis BH, Polonsky WH. Exploring the role of the patient-physician relationship on insulin adherence and clinical outcomes in type 2 diabetes: Insights from the MOSAIc study. J Diabetes. 2017;9(6):596–605.CrossRefPubMed
38.
Pantalone KM, Viljoen A, Galindo RJ, Cui X, Huh R, Fernández Landó L, et al. Patients with type 2 diabetes reach glycemic targets faster with tirzepatide compared to semaglutide and titrated insulin degludec. American Diabetes Association—82nd Annual Scientific Sessions; New Orleans, LA, USA; 3–7 June 2022.
39.
Lingvay I, Giorgino F, Van Gaal LF, Liu M, Rodríguez A, Torcello-Gómez A, et al. Early weight loss and late metabolic outcomes in tirzepatide-treated participants with type 2 diabetes. American Diabetes Association – 83rd Annual Scientific Sessions; 23–26 June San Diego, CA, USA2023.
40.
41.
Committee ADAPP. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2021;45(Supplement_1):S185–94.
42.
43.
The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.CrossRefPubMedCentral
44.
Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591–8.CrossRefPubMedPubMedCentral
45.
Lingvay I, Mosenzon O, Brown K, Cui X, O’Neill C, Fernández Landó L, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc Diabetol. 2023;22(1):66.CrossRefPubMedPubMedCentral
46.
Lingvay I, Mosenzon O, Brown K, Cui X, Lando LF, Patel H. 716-P: systolic blood pressure reduction with tirzepatide across SURPASS program: a mediation analysis using weight loss as a factor. Diabetes. 2022;71(Supplement_1):716–51.
47.
Gomez-Peralta F, Abreu C, Lecube A, Bellido D, Soto A, Morales C, et al. Practical approach to initiating SGLT2 inhibitors in type 2 diabetes. Diabetes Ther. 2017;8(5):953–62.CrossRefPubMedPubMedCentral
48.
Patel H, Khunti K, Rodbard HW, Bajaj HS, Bray R, Kindracki Z, Rodríguez Á. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obes Metab. 2024;26(2):473–81. https://​doi.​org/​10.​1111/​dom.​15333
49.
Reid TS. Practical use of glucagon-like peptide-1 receptor agonist therapy in primary care. Clinical Diabetes. 2013;31(4):148–57.CrossRef
50.
Gray A, Threlkeld RJ. Nutritional Recommendations for Individuals with Diabetes. [Updated 2019 Oct 13]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
51.
Gonzalez-Campoy JM, St Jeor ST, Castorino K, Ebrahim A, Hurley D, Jovanovic L, Mechanick JI, Petak SM, Yu YH, Harris KA, Kris-Etherton P, Kushner R, Molini-Blandford M, Nguyen QT, Plodkowski R, Sarwer DB, Thomas KT; American Association of Clinical Endocrinologists; American College of Endocrinology and the Obesity Society. Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society. Endocr Pract. 2013;19 Suppl 3:1–82. https://​doi.​org/​10.​4158/​EP13155.​GL
52.
Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, Castro A, Cebrián-Cuenca A, de Torres-Sánchez A, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12(1):145.CrossRef
53.
Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical Activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065–79.CrossRefPubMedPubMedCentral
54.
Harrington D, Henson J. Physical activity and exercise in the management of type 2 diabetes: where to start? Pract Diabetes. 2021;38(5):35–40b.CrossRef
Metadata
Title
Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects
Authors
Luis A. Vázquez
Santiago Tofé-Povedano
Diego Bellido-Guerrero
Marta Botella-Serrano
Alfonso Soto-González
Pedro Mezquita-Raya
Elías Delgado
Carmen Fajardo-Montañana
Cristóbal Morales-Portillo
Ana Causanilles
Miriam Rubio-de Santos
Irene Romera
Esteban Jódar-Gimeno
Publication date
09-05-2024
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 7/2024
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-024-01587-6

Other articles of this Issue 7/2024

Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide

The Efficacy and Safety of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors in Real-World Clinical Practice: Potential Cautionary Use in Elderly Patients with Type 2 Diabetes (T2D)

Therapy-Related Satisfaction and Quality of Life for Japanese People with Diabetes Using Rapid-Acting Insulin Analogs: A Web-Based Survey

  • Open Access
  • Insulins
  • Original Research

Urban–Rural Differences in the Prevalence of Diabetes Among Adults in Haryana, India: The ICMR-INDIAB Study (ICMR-INDIAB-18)

Efficacy of Self-Review of Lifestyle Behaviors with Once-Weekly Glycated Albumin Measurement in People with Type 2 Diabetes: A Randomized Pilot Study

Changes in Basal and Bolus Insulin Requirements with Tirzepatide as an Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar
Image Credits